Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
LTR Pharma Limited ( (AU:LTP) ) has issued an update.
LTR Pharma Limited announced its 2025 Annual General Meeting, highlighting its ongoing efforts to expand its market presence and product pipeline. The company’s focus on strategic partnerships and regulatory advancements aims to enhance its global footprint and deliver patient-centric treatments, reflecting its commitment to improving quality of life for patients with significant medical needs.
More about LTR Pharma Limited
LTR Pharma is a commercial-stage pharmaceutical company focused on delivering innovative therapies for unmet medical needs through its proprietary intranasal drug delivery platform. The company has commercialized its rapid-acting treatment technology in Australia and is expanding into the US and other key markets. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for erectile dysfunction, and it is developing OROFLOW for Oesophageal Motility Disorders.
Average Trading Volume: 880,428
Technical Sentiment Signal: Buy
Current Market Cap: A$97.16M
See more insights into LTP stock on TipRanks’ Stock Analysis page.